AA
TARS icon

ALPS Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

ALPS Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
43,365
+8,718
+25% +$557K 0.01% 433
2026
Q1 		$2.43M Sell
34,647
-108
-0.3% -$7.55K 0.01% 369
2025
Q4 		$2.85M Buy
34,755
+13,303
+62% +$993K 0.02% 333
2025
Q3 		$1.27M Sell
21,452
-1,226
-5% -$60.4K 0.01% 472
2025
Q2 		$919K Sell
22,678
-5,158
-19% -$232K 0.01% 517
2025
Q1 		$1.43M Sell
27,836
-3,070
-10% -$152K 0.01% 401
2024
Q4 		$1.71M Buy
30,906
+1,664
+6% +$75.6K 0.01% 365
2024
Q3 		$962K Sell
29,242
-226
-0.8% -$6.35K 0.01% 498
2024
Q2 		$801K Buy
29,468
+3,020
+11% +$102K 0.01% 511
2024
Q1 		$961K Buy
26,448
+4,621
+21% +$136K 0.01% 496
2023
Q4 		$442K Sell
21,827
-2,278
-9% -$38K ﹤0.01% 625
2023
Q3 		$428K Buy
24,105
+4,404
+22% +$77.9K ﹤0.01% 618
2023
Q2 		$356K Buy
19,701
+2,132
+12% +$33.9K ﹤0.01% 713
2023
Q1 		$221K Sell
17,569
-507
-3% -$7.42K ﹤0.01% 974
2022
Q4 		$265K Buy
+18,076
New +$299K ﹤0.01% 940

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ALPS Advisors's TARS Position: Q2 2026 in Review

ALPS Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 25% in Q2 2026, buying an estimated $557K and bringing the position to 43,365 shares worth $2.73M. The position accounts for 0.01% of the portfolio, ranked #433.

ALPS Advisors first reported a position in TARS in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.85M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • ALPS Advisors held 43,365 shares of Tarsus Pharmaceuticals worth $2.73M as of Q2 2026.
  • ALPS Advisors bought 8,718 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $557K.
  • Tarsus Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #433 holding.
  • ALPS Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • ALPS Advisors's Tarsus Pharmaceuticals position peaked at $2.85M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.